Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcrisantaspase and venetoclax in R/R AML
NCT04666649Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Mar 2021
- Primary completion
- Sep 2024
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegcrisantaspase in acute myeloid leukemia (AML), sponsored by University of Maryland, Baltimore. Started Mar 2021; status: completed.
02
Drugs
pegcrisantaspase
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04666649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666649.